在药物发现中分子对接的现实应用
Somenath Dutta1, Indrani Biswas2, Subhabrata Goswami3
1Department of Chemical & Biomolecular Engineering, Pusan National University, Busan, South Korea.
Advances in pharmacology (San Diego, Calif.)
|April 2, 2025
概括
使用分子对接的计算药物设计快速选植物化学物质,以对抗SARS-CoV-2变种,如XBB.1.5.5. 这种虚拟查可以识别出有前途的广泛抗病毒药物,加速对不断变化的病毒的治疗开发.
科学领域:
- 计算化学是一种计算化学.
- 药物发现 药物发现
- 病毒学 病毒学
背景情况:
- 分子对接是用于虚拟查的关键计算药物设计技术.
- 像SARS-CoV-2这样快速演变的病原体对药物开发构成了持续的挑战.
- 新变种,如SARS-CoV-2 XBB.1.5,需要适应性治疗策略.
研究的目的:
- 选植物化学物质作为潜在的治疗剂对抗SARS-CoV-2 XBB.1.5尖端蛋白变体.
- 评估潜在候选药物的结合亲和力,药理动力学和毒性.
- 突出计算方法在打击病毒演变中的实用性.
主要方法:
- 对SARS-CoV-2 XBB.1.5尖端蛋白进行了分子对接模拟.
- 施罗丁格的套件,瑞士ADME和ProTox-II被用于虚拟选和标识.
- 结合亲和力,药理动力学特性和毒性概况是通过计算估计的.
主要成果:
- 确定了有前途的化合物,它们对突变的尖端蛋白具有强烈的结合相互作用.
- 这些已识别的化合物显示出作为广泛的抗病毒药物的潜力.
- 计算工具促进了对多种病毒变异的治疗疗效的评估.
结论:
- 分子对接和相关的计算工具对于应对像SARS-CoV-2这样不断发展的病毒威胁至关重要.
- 这项研究确定了对抗SARS-CoV-2变种有效的潜在的广泛抗病毒植物化学物质.
- 这些方法可用于开发针对各种疾病的向治疗方法.
相关概念视频
Drug Discovery: Overview
7.2K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
7.2K
Ligand Binding Sites
12.6K
Proteins are dynamic macromolecules that carry out a wide variety of essential processes; however, the activities of most proteins depend on their interactions with other molecules or ions, known as ligands.
Protein-ligand interactions are quite specific; even though numerous potential ligands surround a cellular protein at any given time, only a particular ligand can bind to that protein. Moreover, a ligand binds only to a dedicated area on the surface of the protein, known as the...
Protein-ligand interactions are quite specific; even though numerous potential ligands surround a cellular protein at any given time, only a particular ligand can bind to that protein. Moreover, a ligand binds only to a dedicated area on the surface of the protein, known as the...
12.6K
Structure-Activity Relationships and Drug Design
467
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
467
The Equilibrium Binding Constant and Binding Strength
12.7K
The equilibrium binding constant (Kb) quantifies the strength of a protein-ligand interaction. Kb can be calculated as follows when the reaction is at equilibrium:
12.7K
Drug-Receptor Bonds
2.6K
Drug-receptor bonds are formed through various chemical forces when drugs interact with target cells. Covalent bonds, strong and irreversible, are exemplified by DNA-alkylating anticancer agents that inhibit cell division. However, such irreversible drug binding lacks selectivity and can modify the DNA of the surrounding healthy cells. Covalent binding often contributes to tissue toxicity, as seen with chloroform and paracetamol metabolites binding to the liver, causing hepatotoxicity.
In...
In...
2.6K
Targets for Drug Action: Overview
5.9K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
5.9K


